Serum integrin-linked kinase (sILK) concentration and survival in non-small cell lung cancer: a pilot study

Background Integrin-linked kinase (ILK) is an intracellular signaling protein critically involved in cellular growth and motility. In non-small cell lung cancer (NSCLC), increased ILK expression has been associated with decreased recurrence-free and overall survival. Recently, ILK has also been dete...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2014-05, Vol.16 (5), p.455-462
Main Authors: Posch, F., Setinek, U., Flores, R. M., Bernhard, D., Hannigan, G. E., Mueller, M. R., Watzka, S. B.
Format: Article
Language:English
Subjects:
Aged
Carcinoma, Non-Small-Cell Lung - blood
Carcinoma, Non-Small-Cell Lung - mortality
Female
Humans
Lung Neoplasms - blood
Lung Neoplasms - mortality
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Pilot Projects
Prospective Studies
Protein-Serine-Threonine Kinases - blood
Research Article
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Integrin-linked kinase (ILK) is an intracellular signaling protein critically involved in cellular growth and motility. In non-small cell lung cancer (NSCLC), increased ILK expression has been associated with decreased recurrence-free and overall survival. Recently, ILK has also been detected in the serum of NSCLC patients. Objective To assess the prognostic impact of preoperative serum ILK (sILK) concentration on overall survival in surgically amenable NSCLC. Patients and methods Preoperative sILK was quantified by ELISA in 50 newly diagnosed NSCLC patients. After surgery, patients were followed-up for a median interval of 2.5 years. Results Serum ILK concentrations ranged from 0 to 2.44 ng/ml. Mean sILK was around 2.3 times higher in the 16 patients who died as compared to the 34 patients who survived (1.04 vs. 0.45 ng/ml, p  = 0.001). In univariate time-to-event analysis, increased sILK was associated with adverse survival [Hazard ratio (HR): 4.03, 95 % CI: 2.00–8.13, p  
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-013-1101-6